Advertisement

Pharmacy World and Science

, Volume 15, Issue 2, pp 79–82 | Cite as

Pharmacokinetics and clinical study of cefotetan in bile: Prophylactic use in biliary tract surgery

  • P. Cherrier
  • P. Perrin
  • S. Gueye
  • A. M. Bosio
  • P. Tinel
  • P. Blot
  • R. Richer
  • F. Fauvelle
Case Reports Practice

Abstract

The excretion of cefotetan, a 7α-methoxycephalosporin, was studied in 27 patients undergoing biliary surgery. Pharmacokinetic parameters were determined after a single intravenous bolus dose of 1 g (10 patients) or 2 g (17 patients). Rapidly excreted in bile, cefotetan concentrations were considerably higher in bile [range: 92–2,594 mg·l−1 (1 g); 35–4,610 mg·l−1 (2 g)] than in plasma despite the presence of gall stones. Bile bactericidal activities againstStaphylococcus aureus (MIC 8 mg·l−1) andBacteroides fragilis (MIC 2 mg·l−1) correlated well with gall bladder cefotetan levels [r = 0.888 (1 g);r = 0.971 (2 g)]. No cefotetan was detected in the bile of 3 patients with nonfunctioning gall bladders. One other patient with very low activity and these three aside, the inhibitory quotients (cefotetan concentration/MIC) were >4 for both doses against both bacteria.

Keywords

Cefotetan Cholecystectomy Dose-response relationship, drug Pharmacokinetics Prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adam HK, Houghton HL, Yates RA, Young J, Donnelly RJ. Pharmacokinetics and tolerance of a 24 h infusion of cefotetan disodium (with and without loading dose) in normal Caucasian volunteers. J Antimicrob Chemother 1983;11:193–9.Google Scholar
  2. 2.
    Courvalin P, Goldstein F, Philippon A, Sinot J. L'antibiogramme. 3rd ed. Paris: MPC Videom, 1985:195–8, 219–24.Google Scholar
  3. 3.
    Ellner PD, Neu HC. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 1981;246:4.Google Scholar
  4. 4.
    Yates RA, Adam HK, Donnelly RJ, Houghton HL, Charlesworth EA, Laws EA. Pharmacokinetics and tolerance of single intravenous dose of cefotetan disodium in male Caucasian volunteer. J Antimicrob Chemother 1983;11:185–91.Google Scholar
  5. 5.
    Owen AW, Manson JM, Yates RA, Adshead VM, Houghton HL, Tweedle DE. The pharmacokinetics of cefotetan excretion in the unobstructed biliary tract. J Antimicrob Chemother 1983;11:217–21.Google Scholar
  6. 6.
    Kees F, Strehl E, Dominiak P, Grobecker H, Seeger K, Seidel G, et al. Cefotaxime and desacetyl cefotaxime in human bile. Infection 1983;11:118–20.Google Scholar
  7. 7.
    Grion JA, Meyers BR, Hirschman SZ. Biliary concentrations of piperacillin in patients undergoing cholecystectomy. Antimicrob Agents Chemother 1981;19:309–11.Google Scholar
  8. 8.
    Ratzan KR, Baker HB, Lauredo I. Excretion of cefamandole, cefazolin and cephalothin into T-tube bile. Antimicrob Agents Chemother 1978;13:985–7.Google Scholar
  9. 9.
    Martinez OV, Levi JU, Malinin Tl, Zeppa R. In: Program Abstracts of the Interscience Conference on Antimicrobial Agents Chemotherapy. Las Vegas; Nevada; 1983. Washington: American Society of Antimicrobial Agents Chemotherapy, 1983:abstract 709.Google Scholar
  10. 10.
    Neu HC. A review and summary of the pharmacokinetics of cefoperazone: a new extended spectrum of beta-lactam antibiotics. Ther Drug Monitor 1981;3:121–8.Google Scholar
  11. 11.
    Levi JU, Livingstone A, Martinez OV, Zeppa R, Malinin Tl, Hutson D, et al. Biliary concentrations of cefamandole and its use in biliary tract surgery. Scand J Infect Dis 1981;25 Suppl:55–7.Google Scholar
  12. 12.
    Ratzan KR, Ruiz C, Irvin GL. Biliary tract excretion of cefazolin, cephalothin and cephaloridine in the presence of biliary tract disease. Antimicrob Agents Chemother 1974;6:426–31.Google Scholar
  13. 13.
    Strasberg SM, Harvey RPC, Hofmann AF. Bile sampling, processing and analysis in clinical studies. Hepatology 1990;12:176S-82S.Google Scholar
  14. 14.
    Ahrendt SA, Magnusson TH, Pitt HA, Lillemoe KD. Effect of cholecystectomy on gallbladder bile composition. Dig Dis Sci 1992;37:1232–5.Google Scholar
  15. 15.
    Martinez OV, Levi JU, Devlin RG. Biliary excretion of aztreonam in patients with biliary tract disease. Antimicrob Agents Chemother 1984;25:358–61.Google Scholar
  16. 16.
    Leung JWC, Chan CY, Lai CW, Ko TC, Cheng AFB, French GL. Effect of biliary obstruction on the hepatic excretion of imipenem-cilastatin. Antimicrob Agents Chemother 1992;36:2057–60.Google Scholar
  17. 17.
    Tera H. Stratification of human gallbladder bilein vivo. Acta Chir Scand 1960;256 Suppl:4–85.Google Scholar

Copyright information

© Periodicals Service Company 1993

Authors and Affiliations

  • P. Cherrier
    • 1
  • P. Perrin
    • 1
  • S. Gueye
    • 3
  • A. M. Bosio
    • 1
  • P. Tinel
    • 2
  • P. Blot
    • 2
  • R. Richer
    • 3
  • F. Fauvelle
    • 1
  1. 1.Service de PharmacieCentre Hospitalier Intercommunal de MontfermeilMontfermeilFrance
  2. 2.Service d'AnesthésieCentre Hospitalier Intercommunal de MontfermeilFrance
  3. 3.Service de Chirurgie ViscéraleCentre Hospitalier Intercommunal de MontfermeilFrance

Personalised recommendations